Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
E-pub ahead of print

Effects of the chymase inhibitor fulacimstat in diabetic kidney disease-results from the CADA DIA trial

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Adrenal insufficiency in kidney transplant patients during low-dose prednisolone therapy: a cross-sectional case-control study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Rapid decline in 51Cr-ethylenediaminetetraacetic acid-measured renal function during the first weeks following liver transplantation

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Meta-analysis uncovers genome-wide significant variants for rapid kidney function decline

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Changes in Albuminuria Predict Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Post Hoc Analysis of the LEADER Trial

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Data Sharing Under the General Data Protection Regulation: Time to Harmonize Law and Research Ethics?

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Finerenone and Cardiovascular Outcomes in Patients with Chronic Kidney Disease and Type 2 Diabetes

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Peter Rossing
  • Jorma Strand
  • Angelo Avogaro
  • Michael Becka
  • Friederike Kanefendt
  • Christiane Otto
View graph of relations

BACKGROUND: The protease chymase generates multiple factors involved in tissue remodelling including angiotensin II (Ang II) and has been implicated in the pathophysiology of diabetic kidney disease (DKD). This study investigated the effects of the chymase inhibitor fulacimstat on albuminuria in patients with Type II diabetes mellitus and a clinical diagnosis of DKD.

METHODS: In this double-blind, randomized, placebo-controlled trial, patients were on the maximum tolerated dose of either an Ang II receptor blocker or an Ang-converting enzyme inhibitor since at least 3 months before the screening visit. Eligible patients were randomized in a 2:1 ratio to treatment with either 25 mg fulacimstat (n = 99) or placebo (n = 48) twice daily on top of standard of care.

RESULTS: The randomized patients had a mean urine albumin-creatinine ratio (UACR) of 131 mg/g (range: 29-2429 mg) and a mean (standard deviation) estimated glomerular filtration rate of 60.8 ± 16.9 mL/min/1.73 m2 before treatment start. Fulacimstat was safe and well tolerated, and achieved mean total trough concentrations that were ∼9-fold higher than those predicted to be required for minimal therapeutic activity. UACR increased by 27.4% [coefficient of variation (CV) 86%] and 3% (CV 88.9%) after 24 weeks of treatment with placebo or fulacimstat, respectively. Analysis of covariance revealed a least square mean UACR ratio (fulacimstat/placebo) of 0.804 (90% CI 0.627-1.030, P = 0.1477), indicating a statistically non-significant UACR reduction of 19.6% after fulacimstat treatment compared with placebo.

CONCLUSIONS: Fulacimstat was safe and well tolerated but did not reduce albuminuria in patients with DKD. These findings do not support a therapeutic role for chymase inhibition in DKD.

Original languageEnglish
JournalNephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
ISSN0931-0509
DOIs
Publication statusE-pub ahead of print - 26 Dec 2020

ID: 61613683